Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease
eLife · 2026
DOI: 10.7554/elife.110149 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Conor J Howard und 23 weiteren Autor:innen. Beteiligte Einrichtung: Octant, Inc, Emeryville, United States. Hauptthemen laut MEDLINE: Autoimmune Diseases, Signal Transduction, TYK2 Kinase. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Tyrosine kinase 2 (TYK2) is a genetically defined target for autoimmune disease, with first-generation inhibitors showing clinical success in some but not all associated indications. A deeper understanding of TYK2 structure-function relationships, protein-ligand interactions, and the impact of human variants could inform next-generation therapeutics. Here, we applied deep mutational scanning (DMS) to assess >23,000 amino acid substitutions across two TYK2 functions: interferon alpha (IFN-α) signaling and protein abundance. This enabled high-resolution structure-function mapping and the identification of novel allosteric sites. By coupling DMS with inhibitor treatment, we uncovered variants that modulate compound potency. We also show that human variants – both common and rare – that are protective against autoimmune phenotypes reduce TYK2 protein abundance. Together, these findings demonstrate that DMS can prospectively reveal novel druggable sites, clarify structure-activity relationships (SAR), and highlight TYK2 degradation as a potential therapeutic strategy in autoimmunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Octant, Inc, Emeryville, United States.
- Bristol-Myers Squibb, New York, United States.
ORCID-Profile: Conor J Howard, Nathan S Abell, Robert R Warneford-Thomson, Sriram Kosuri, Diane E Dickel
Förderung
- Bristol Myers Squibb
Zitieren
APA
Howard, C. J., Abell, N. S., Warneford-Thomson, R. R., Mahdavi, E., Su, A. L., Resnick, C., Mohammed, N., Thompson, E. M., Holzinger, E. R., Catalano, K., Hukku, A., Mintier, G. A., MacKenzie, M., Jiang, B. L., Barbosa Rabago, D., Chan, A., Ntimi, C., Weiler, K. N., Wilson, S. C., …, & Dickel, D. E. (2026). Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease. eLife. https://doi.org/10.7554/elife.110149
Vancouver
Howard CJ, Abell NS, Warneford-Thomson RR, Mahdavi E, Su AL, Resnick C, et al. Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease. eLife. 2026. doi:10.7554/elife.110149
BibTeX
@article{Howard2026,
author = {Howard, Conor J and Abell, Nathan S and Warneford-Thomson, Robert R and Mahdavi, Eden and Su, Alan L and Resnick, Carmen and Mohammed, Nabil and Thompson, Erin M and Holzinger, Emily R and Catalano, Katrina and Hukku, Abhay and Mintier, Gabriel A and MacKenzie, Morgan and Jiang, Bryan L and Barbosa Rabago, Dora and Chan, Angela and Ntimi, Carolindah and Weiler, Kaitlyn N and Wilson, Stephen C and Maranville, Joseph C and Sheth, Payal R and Plenge, Robert M and Kosuri, Sriram and Dickel, Diane E},
title = {Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.110149}
}
EUVIMED